C Lambek
About
In The Last Decade
C Lambek
24 papers receiving 806 citations
Peers
Comparison fields: 5 of 66
- Hematology 564
- Genetics 339
- Molecular Biology 232
- Rheumatology 178
- Oncology 165
Countries citing papers authored by C Lambek
This map shows the geographic impact of C Lambek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Lambek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Lambek more than expected).
Fields of papers citing papers by C Lambek
This network shows the impact of papers produced by C Lambek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Lambek. The network helps show where C Lambek may publish in the future.
Co-authorship network of co-authors of C Lambek
This figure shows the co-authorship network connecting the top 25 collaborators of C Lambek. A scholar is included among the top collaborators of C Lambek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Lambek. C Lambek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 30 | |
| 2 | 31 | |
| 3 | 83 | |
| 4 | Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. | 12 |
| 5 | Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. | 135 |
| 6 | 8 | |
| 7 | 59 | |
| 8 | 10 | |
| 9 | 6 | |
| 10 | Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand. | 19 |
| 11 | 29 | |
| 12 | Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination. | 30 |
| 13 | Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia. | 8 |
| 14 | Discordant maturation as the primary biological defect in chronic myelogenous leukemia. | 56 |
| 15 | 24 | |
| 16 | 16 | |
| 17 | 128 | |
| 18 | 3 | |
| 19 | 43 | |
| 20 | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.